Familial hypertriglyceridemia is a genetic disorder where the liver produces too much fat that circulates in the blood, creating risks for the heart and other organs. For people with this condition, managing triglyceride levels through both lifestyle adjustments and medical treatments becomes essential to prevent serious complications and maintain long-term health.

Understanding Treatment Goals and Approaches

The main purpose of treating familial hypertriglyceridemia is to bring down the elevated levels of triglycerides, which are fatty substances in the blood, to safer ranges. This reduction helps protect against two major concerns: heart disease and inflammation of the pancreas called pancreatitis. Treatment strategies depend heavily on how high the triglyceride levels are, whether other health conditions exist alongside the disorder, and the individual’s response to different therapies.^[1]

People with familial hypertriglyceridemia typically have triglyceride levels ranging from about 200 to 500 milligrams per deciliter, though some may have much higher readings. When triglyceride levels climb above 500 milligrams per deciliter, the risk of developing acute pancreatitis increases significantly. This dangerous inflammation of the pancreas requires urgent attention and prevention becomes a critical treatment goal.^[2]

Medical societies and healthcare organizations have established standard treatments that doctors use as first-line approaches for this condition. These approved therapies have been tested and proven helpful in many patients over time. However, because familial hypertriglyceridemia is complex and affects people differently, researchers continue exploring new treatment options through clinical trials. These investigational therapies aim to provide better results for patients who don’t respond well to existing medications or who experience troublesome side effects.^[1]

Treatment must be personalized based on each person’s genetic makeup, the severity of their triglyceride elevation, and other medical conditions they may have. For instance, many people with familial hypertriglyceridemia also struggle with obesity, high blood sugar levels, high blood pressure, or insulin resistance. These overlapping conditions can make triglyceride levels even worse and must be addressed as part of the overall treatment plan.^[3]

Standard Medical Treatment Approaches

The foundation of standard treatment for familial hypertriglyceridemia begins with lifestyle modifications before any medication is prescribed. Doctors emphasize these changes because they can make a substantial difference in triglyceride levels without the side effects that sometimes come with drugs. Weight loss stands as one of the most effective non-medication approaches. Even losing a modest amount of weight, such as five percent of body weight, can improve triglyceride levels and reduce other cardiovascular risk factors.^[8]

Dietary changes play a central role in managing this condition. People with familial hypertriglyceridemia benefit from reducing their intake of simple carbohydrates and refined sugars, which the body quickly converts into triglycerides. Foods high in saturated fats should also be limited. Instead, the diet should emphasize vegetables, fruits, whole grains, and sources of omega-3 fatty acids such as salmon, herring, and sardines. These healthy fats help lower triglyceride levels through different mechanisms than medications.^[2]

Alcohol consumption deserves special attention in people with this disorder. Even small amounts of alcohol can push triglyceride levels higher in susceptible individuals. Complete avoidance of alcoholic beverages is often recommended, particularly for those with severe elevations. Similarly, certain medications like some birth control pills containing estrogen can worsen hypertriglyceridemia. Women with this condition should discuss alternative contraceptive options with their healthcare providers.^[11]

Physical activity provides multiple benefits beyond just lowering triglycerides. Regular exercise, particularly moderate to high-intensity aerobic activity for at least 30 minutes on most days, helps reduce triglyceride levels, improves body composition, and enhances the way the body processes fats. Exercise also increases insulin sensitivity, which is particularly important since many people with familial hypertriglyceridemia have insulin resistance.^[8]

When lifestyle changes don’t bring triglyceride levels down to safe ranges, or when levels are dangerously high from the start, medications become necessary. Several classes of drugs have proven effective in lowering triglycerides in people with familial hypertriglyceridemia.^[10]

Fibrates represent one of the primary medication classes used to treat elevated triglycerides. These drugs, which include gemfibrozil and fenofibrate, work by activating specific receptors in the body that increase the breakdown of triglyceride-rich particles and reduce the liver’s production of these fats. Fibrates can lower triglyceride levels by 30 to 50 percent in many patients. Common side effects include stomach upset, muscle aches, and in rare cases, muscle breakdown. Regular monitoring of liver and kidney function is needed when taking fibrates.^[2]

Nicotinic acid, also called niacin, is another medication that effectively lowers triglycerides. It works through multiple mechanisms, including reducing the liver’s production of very low-density lipoproteins (VLDL), which are particles loaded with triglycerides. Niacin can lower triglyceride levels by 20 to 50 percent. However, it frequently causes flushing, a sensation of warmth and redness in the face and upper body, which many people find uncomfortable. Other side effects can include itching, stomach problems, and worsening of blood sugar control in people with diabetes. Taking niacin with food or using extended-release formulations may reduce side effects.^[11]

Omega-3 fatty acid preparations available by prescription contain high doses of specific omega-3s derived from fish oil. These medications help lower triglycerides by reducing the liver’s production of VLDL and increasing the clearance of triglyceride-rich particles from the bloodstream. Prescription omega-3 products can reduce triglyceride levels by 20 to 50 percent depending on the dose. Side effects are generally mild and include fishy aftertaste, upset stomach, and easy bruising in some people.^[10]

Statins, which are primarily used to lower cholesterol, may also be prescribed for people with familial hypertriglyceridemia, especially if they have other cardiovascular risk factors. While statins are less effective at lowering triglycerides compared to fibrates or niacin, they provide important benefits by reducing the risk of heart attack and stroke. High-potency statins such as atorvastatin and rosuvastatin at higher doses can modestly lower triglyceride levels while significantly reducing bad cholesterol. Statins work by blocking an enzyme the liver needs to make cholesterol, which indirectly affects triglyceride metabolism as well.^[10]

For patients with very high triglyceride levels above 500 milligrams per deciliter, preventing pancreatitis becomes the immediate treatment priority. In these cases, aggressive therapy with fibrates, omega-3 fatty acids, or niacin is typically started right away rather than waiting to see if lifestyle changes work. Combination therapy using more than one medication may be necessary to bring levels down quickly and keep them in a safer range.^[8]

The duration of treatment for familial hypertriglyceridemia is usually lifelong. Because this is a genetic condition, the underlying tendency to produce too many triglycerides doesn’t go away. People typically need to continue their medications indefinitely while maintaining lifestyle modifications. Regular monitoring with blood tests helps doctors adjust medication doses and ensure treatments remain effective over time.^[1]

Emerging Treatments Being Studied in Clinical Trials

Research into new therapies for hypertriglyceridemia has accelerated in recent years, with several promising medications currently being tested in clinical trials. These investigational treatments use innovative approaches to target the biological processes that regulate triglyceride levels more precisely than older medications.^[9]

One exciting area of research focuses on drugs that block apolipoprotein C-III, or apoC-III, a protein that plays a key role in how the body handles triglycerides. ApoC-III inhibits the enzyme lipoprotein lipase, which normally breaks down triglycerides in the blood. By reducing apoC-III levels, these new medications allow lipoprotein lipase to work more effectively, leading to lower triglyceride concentrations. Several apoC-III inhibitors are being developed using advanced genetic technologies.^[9]

Olezarsen is an antisense oligonucleotide that reduces the production of apoC-III by interfering with the genetic instructions cells use to make this protein. In clinical trials, olezarsen has been tested in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome, a related but more severe genetic disorder. Early results from Phase II trials showed that olezarsen can reduce triglyceride levels by 50 percent or more in many patients. The medication is given as an injection under the skin, typically once every one to three months. Side effects observed in trials have included injection site reactions and mild decreases in platelet counts, but serious complications have been rare.^[9]

Plozasiran represents another apoC-III inhibitor but uses a different genetic technology called small interfering ribonucleic acid, or siRNA. This approach also reduces apoC-III production but may require less frequent dosing. Phase II trials of plozasiran have demonstrated significant triglyceride reductions in patients with severe hypertriglyceridemia. The drug appears to have a favorable safety profile, with fewer concerns about platelet reduction compared to earlier apoC-III inhibitors. Patients in these trials received injections every few months and experienced sustained lowering of their triglyceride levels.^[9]

Another molecular target being explored in clinical trials is angiopoietin-like protein 3, or ANGPTL3. This protein inhibits lipoprotein lipase similar to apoC-III, so blocking ANGPTL3 helps the body break down triglycerides more efficiently. Zodasiran is a new ANGPTL3 inhibitor using siRNA technology that has shown promise in Phase II trials. In studies involving patients with moderate hypertriglyceridemia, zodasiran produced significant reductions in triglyceride levels along with improvements in other lipid measurements. The medication is administered by injection and appears well-tolerated, with side effects comparable to placebo in most patients.^[9]

Pegozafermin represents a completely different approach to treating severe hypertriglyceridemia. This medication is an analog of fibroblast growth factor 21, or FGF21, a natural hormone that regulates fat metabolism. FGF21 helps cells burn fat more efficiently and reduces the liver’s production of triglycerides. Pegozafermin mimics these beneficial effects while lasting longer in the body than natural FGF21. Phase II clinical trials have shown that pegozafermin can reduce triglyceride levels substantially in patients with severe hypertriglyceridemia. The drug is given as a weekly injection under the skin. Beyond lowering triglycerides, pegozafermin has also shown beneficial effects on body weight and liver fat in trial participants.^[9]

High-dose icosapent ethyl, sold under the brand name Vascepa, deserves special mention as it bridges standard treatment and newer therapies. This purified form of the omega-3 fatty acid eicosapentaenoic acid has been tested extensively in Phase III trials. The REDUCE-IT trial, a large study involving patients with elevated triglycerides who were already taking statins for cardiovascular disease, showed that icosapent ethyl at 4 grams daily reduced the risk of cardiovascular death, heart attack, and stroke. Specifically, treatment with icosapent ethyl prevented one cardiovascular death for every 111 patients treated over five years. This medication has already been approved by regulatory authorities in several countries based on these results.^[8]

Clinical trials for hypertriglyceridemia treatments are being conducted at medical centers across many countries, including in the United States, Europe, and other regions. Patient eligibility for these trials depends on specific criteria such as triglyceride levels, other health conditions, current medications, and willingness to follow the study protocol. Most trials require that participants have triglyceride levels above certain thresholds and may exclude people with certain other medical problems. Those interested in participating can discuss options with their healthcare providers or search clinical trial registries online.^[9]

The mechanisms by which these new medications work offer advantages over traditional therapies. Antisense oligonucleotides and siRNA therapies target the production of specific proteins at the genetic level, offering very precise effects. These medications can be dosed less frequently than daily pills because they last longer in the body. The injection-based administration, while less convenient than oral medications for some people, allows for better control over drug levels and may improve adherence since patients don’t need to remember daily doses.^[9]

Early evidence from clinical trials suggests that many of these investigational therapies may be safer than some older medications. For example, earlier apoC-III inhibitors caused significant drops in platelet counts in some patients, raising concerns about bleeding risk. Newer versions like olezarsen and plozasiran appear to cause less platelet reduction while still effectively lowering triglycerides. However, long-term safety data are still being collected as these medications move through later stages of testing.^[9]

Preliminary results from trials have been encouraging in terms of how much these new drugs reduce triglycerides. Many patients in Phase II trials experienced triglyceride reductions of 50 percent or more, which is substantial and potentially life-changing for those with very high levels. Some medications also improved other lipid measurements, such as lowering bad cholesterol or raising good cholesterol, providing additional cardiovascular benefits.^[9]

Most common treatment methods

• Lifestyle Modifications
  • Weight loss of 5 percent or more through diet and exercise programs
  • Dietary changes emphasizing reduced carbohydrates, especially refined sugars, and increased omega-3 fatty acids from fish
  • Regular moderate to high-intensity physical activity for at least 30 minutes on most days
  • Complete avoidance of alcohol in many cases
  • Smoking cessation to reduce cardiovascular risk
• Fibrate Medications
  • Gemfibrozil and fenofibrate, which activate receptors to increase triglyceride breakdown
  • Can lower triglyceride levels by 30 to 50 percent
  • Require monitoring of liver and kidney function during treatment
• Omega-3 Fatty Acids
  • Prescription-strength omega-3 preparations containing high doses of eicosapentaenoic acid
  • Reduce liver production of triglyceride-rich particles
  • High-dose icosapent ethyl shown to reduce cardiovascular events in clinical trials
• Niacin (Nicotinic Acid)
  • Reduces liver production of very low-density lipoproteins
  • Can lower triglycerides by 20 to 50 percent
  • May cause flushing and other side effects that limit use
• Statin Medications
  • Primarily lower cholesterol but provide modest triglyceride reduction
  • High-potency statins like atorvastatin and rosuvastatin at higher doses
  • Reduce cardiovascular risk through multiple mechanisms
• ApoC-III Inhibitors (Investigational)
  • Olezarsen and plozasiran use genetic technologies to reduce apoC-III protein
  • Administered by injection every one to three months
  • Can reduce triglycerides by 50 percent or more in clinical trials
• ANGPTL3 Inhibitors (Investigational)
  • Zodasiran blocks a protein that inhibits triglyceride breakdown
  • Tested in Phase II trials for moderate hypertriglyceridemia
  • Given by injection with favorable tolerability profile
• FGF21 Analogs (Investigational)
  • Pegozafermin mimics a natural hormone that regulates fat metabolism
  • Weekly injections in clinical trials for severe hypertriglyceridemia
  • Shows effects on body weight and liver fat beyond triglyceride reduction